Navigation Links
Pfizer unveils anti-smoking drug

Pfizer's new drug was inspired by a natural remedy tested by doctors in the Soviet Union in the late 1960s. The Soviet doctors had tested a chemical called cytisine, derived from a weed sometimes called false tobacco, as a pill to help smokers kick the habit. They reported that cytisine partially activated the nicotine receptors in the brain without being addictive.
Pfizer Inc. unveiled an experimental drug to help people quit smoking //that could become the drugmaker's next blockbuster.

In clinical trials involving several hundred smokers, the New York-based company said almost half of smokers given this oral medicine, called Varenicline, were able to quit smoking after only seven weeks.

In the same trial, only 16 percent of people receiving sugar pills managed to stop, while 33 percent of patients who received Zyban, a pill sold as Wellbutrin for depression, were able to quit.

"This is a significant improvement over results achieved with Zyban, an antidepressant approved as an aid to smoking cessation." Side effects of the Pfizer drug appeared negligible so far, and the drug has "an excellent safety profile," said Pfizer's spokeswoman.

Varenicline is currently in the final phase of widespread human clinical trials, but there's no timeline for when the anti-smoking drug might hit the market.

The company, however, cautioned that the results of its big clinical studies will take time, and a positive outcome isn't always guaranteed. Pfizer said it is unclear how long patients need to be on Varenicline after quitting.
'"/>




Page: 1

Related medicine news :

1. The Effectiveness Of The Breast Cancer Drug By Pfizer
2. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
3. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
4. Pfizer’s Eraxis Approved By The FD
5. Pfizer Launches Viagra For Lung Disease In UK
6. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
7. Pfizer Commences Its Advertising for Celebrex with All the Warnings
8. FDA Approves Pfizer’s Anti-smoking Dru
9. Pfizer vouches safety of long-term inhaled insulin.
10. NICE Setback Rules for Pfizers Inhaled Insulin
11. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: